Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891364 | 1.00 | HCAR2 (0.43) | HCAR2KEAP1NFE2L2CA12AKR1B10 | |
| SCHEMBL27511152 | 0.92 | HCAR2 (0.57) | HCAR2 | |
| SCHEMBL9809844 | 0.92 | HCAR2 (0.57) | HCAR2 | |
| SCHEMBL3697116 | 0.90 | HCAR2 (0.35) | HCAR2 | |
| SCHEMBL3697113 | 0.90 | HCAR2 (0.35) | HCAR2 | |
| SCHEMBL10854431 | 0.88 | HCAR2 (0.47) | HCAR2CA12CA1CA2CA7 | |
| SCHEMBL10854417 | 0.88 | HCAR2 (0.47) | HCAR2CA12CA1CA2CA7 | |
| Ethylene Glycol SCHEMBL3701779 | 0.84 | HCAR2 (0.32) | HCAR2 | |
| SCHEMBL195840 | 0.83 | TSHR (0.39) | — | |
| SCHEMBL21409479 | 0.82 | TSHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747295-A1 | OPTICAL MATERIAL DERIVED FROM A PREPOLYMER OBTAINED FROM A HETERODIFUNCTIONAL ALKYNE COMPOUND | ESSILOR INTERNATIONAL (FR) | 2026-05-27 | — | — | EP | claimed |
| EP-4747293-A1 | OPTICAL MATERIAL DERIVED FROM A POLYMERIZABLE COMPOSITION CONTAINING A TERMINAL DIALKYNE COMPOUND | ESSILOR INTERNATIONAL (FR) | 2026-05-27 | — | — | EP | claimed |
| EP-4747294-A1 | OPTICAL MATERIAL DERIVED FROM A POLYMERIZABLE COMPOSITION CONTAINING A HETERODIFUNCTIONAL ALKYNE COMPOUND | Essilor International (FR) | 2026-05-27 | — | — | EP | claimed |
| US-20260117015-A1 | METHOD OF CURING A POLYTHIOURETHANE BASED SUBSTRATE WITH A SALT CATALYST | ESSILOR INT (FR) | 2026-04-30 | — | — | US | claimed |
| EP-4634258-A1 | METHOD OF CURING A POLYTHIOURETHANE BASED SUBSTRATE TOLERANT TO WATER | Essilor International (FR) | 2025-10-22 | — | — | EP | claimed |
| EP-4598973-A1 | METHOD OF CURING A POLYTHIOURETHANE BASED SUBSTRATE WITH A SALT CATALYST | Essilor International (FR) | 2025-08-13 | — | — | EP | claimed |
| WO-2025017197-A1 | OPTICAL MATERIAL DERIVED FROM A POLYMERIZABLE COMPOSITION CONTAINING A HETERODIFUNCTIONAL ALKYNE COMPOUND | ESSILOR INTERNATIONAL (FR) | 2025-01-23 | — | — | WO | claimed |
| WO-2025017201-A1 | OPTICAL MATERIAL DERIVED FROM A POLYMERIZABLE COMPOSITION CONTAINING A TERMINAL DIALKYNE COMPOUND | ESSILOR INTERNATIONAL (FR) | 2025-01-23 | — | — | WO | claimed |
| WO-2025017198-A1 | OPTICAL MATERIAL DERIVED FROM A PREPOLYMER OBTAINED FROM A HETERODIFUNCTIONAL ALKYNE COMPOUND | ESSILOR INTERNATIONAL (FR) | 2025-01-23 | — | — | WO | claimed |
| WO-2024208839-A1 | METHOD OF CURING A POLYTHIOURETHANE-BASED SUBSTRATE FROM A PRE-POLYMER | ESSILOR INTERNATIONAL (FR) | 2024-10-10 | — | — | WO | claimed |
| EP-4442724-A1 | METHOD OF CURING A POLYTHIOURETHANE-BASED SUBSTRATE FROM A PRE-POLYMER | Essilor International (FR) | 2024-10-09 | — | — | EP | claimed |
| WO-2024126747-A1 | METHOD OF CURING A POLYTHIOURETHANE BASED SUBSTRATE TOLERANT TO WATER | ESSILOR INTERNATIONAL (FR) | 2024-06-20 | — | — | WO | claimed |
| WO-2024074596-A1 | METHOD OF CURING A POLYTHIOURETHANE BASED SUBSTRATE WITH A SALT CATALYST | ESSILOR INTERNATIONAL (FR) | 2024-04-11 | — | — | WO | claimed |
| EP-4747294-A1 | OPTICAL MATERIAL DERIVED FROM A POLYMERIZABLE COMPOSITION CONTAINING A HETERODIFUNCTIONAL ALKYNE COMPOUND | Essilor International (FR) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747293-A1 | OPTICAL MATERIAL DERIVED FROM A POLYMERIZABLE COMPOSITION CONTAINING A TERMINAL DIALKYNE COMPOUND | ESSILOR INTERNATIONAL (FR) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747295-A1 | OPTICAL MATERIAL DERIVED FROM A PREPOLYMER OBTAINED FROM A HETERODIFUNCTIONAL ALKYNE COMPOUND | ESSILOR INTERNATIONAL (FR) | 2026-05-27 | — | — | EP | disclosed |
| US-4446292-A | Moisture curable compositions containing reaction products of hydrophobic polyols and monomer organosilicon-containing substances | PPG INDUSTRIES, INC. (US) | 1984-05-01 | — | — | US | disclosed |
| US-4125570-A | Method of stabilizing the gloss retention of thermosetting resins containing hydroxyl groups | PPG INDUSTRIES, INC. (US) | 1978-11-14 | — | — | US | disclosed |
| US-3962522-A | Poly(esterurethane) coating cured with an aminoplast on a solid substrate | PPG INDUSTRIES, INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3954899-A | URETHANES AND AMINE-ALDEHYDE RESINS | PPG INDUSTRIES, INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117015-A1 | METHOD OF CURING A POLYTHIOURETHANE BASED SUBSTRATE WITH A SALT CATALYST | NCAPH, CTH, CRYAA | HCAR2 3472/4885KEAP1 476/4885NFE2L2 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.